We found that combined radiotherapy and CHK1 inhibition can promote a more favorable immune environment by increasing the presence of antigen-presenting dendritic cells and cytotoxic T cells, which are key players in antitumor immunity in ARID1A-deficient CRC tumors. The gene discussed is CHEK1; the disease is colorectal carcinoma.